Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP – Get Free Report) traded down 3.6% during mid-day trading on Monday . The company traded as low as $1.61 and last traded at $1.62. 49,568 shares were traded during trading, a decline of 54% from the average session volume of 107,078 shares. The stock had previously closed at $1.68.
Wall Street Analysts Forecast Growth
ACXP has been the subject of a number of research analyst reports. Wall Street Zen raised shares of Acurx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings restated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a report on Monday, April 20th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $31.00.
Read Our Latest Stock Analysis on ACXP
Acurx Pharmaceuticals Price Performance
Acurx Pharmaceuticals (NASDAQ:ACXP – Get Free Report) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.03). On average, equities analysts anticipate that Acurx Pharmaceuticals, Inc. will post -1.94 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of the company. Millennium Management LLC purchased a new stake in shares of Acurx Pharmaceuticals during the 4th quarter worth about $103,000. Armistice Capital LLC bought a new position in shares of Acurx Pharmaceuticals during the 2nd quarter valued at $551,000. Geode Capital Management LLC bought a new stake in Acurx Pharmaceuticals in the fourth quarter worth $31,000. Finally, Jane Street Group LLC bought a new position in Acurx Pharmaceuticals during the fourth quarter valued at about $27,000. Hedge funds and other institutional investors own 11.53% of the company’s stock.
About Acurx Pharmaceuticals
Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.
Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).
Featured Stories
- Five stocks we like better than Acurx Pharmaceuticals
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
